AstraZeneca PLC (AZN)
Automate Your Wheel Strategy on AZN
With Tiblio's Option Bot, you can configure your own wheel strategy including AZN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AZN
- Rev/Share 18.2813
- Book/Share 14.4548
- PB 10.6187
- Debt/Equity 0.7343
- CurrentRatio 0.8629
- ROIC 0.1089
- MktCap 475063261200.0
- FreeCF/Share 3.0844
- PFCF 49.6836
- PE 57.0469
- Debt/Assets 0.2921
- DivYield 0.0201
- ROE 0.1991
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AZN | Exane BNP Paribas | -- | Outperform | -- | $75 | April 15, 2025 |
| Upgrade | AZN | UBS | Neutral | Buy | -- | -- | Feb. 13, 2025 |
| Initiation | AZN | Morgan Stanley | -- | Overweight | -- | -- | Feb. 12, 2025 |
| Downgrade | AZN | Deutsche Bank | Hold | Sell | -- | -- | Sept. 13, 2024 |
News
Pharma firms maastraz
Published: April 29, 2025 by: CNBC International TV
Sentiment: Neutral
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
Read More
AstraZeneca shares claw their way back into green after revenue miss
Published: April 29, 2025 by: Proactive Investors
Sentiment: Neutral
After an early stumble, AstraZeneca PLC (LSE:AZN) shares pulled back to level by the close on Tuesday, but analysts see reasons for investors to stay watchful despite the apparent strength of the results. At face value, the update looked reassuring.
Read More
Here's Why Astrazeneca (AZN) is a Strong Value Stock
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
AstraZeneca to keep 2025 forecast if US pharmaceutical tariffs in line with other sectors
Published: April 29, 2025 by: Reuters
Sentiment: Neutral
The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance even if the U.S. levies tariffs on pharma products made in the European Union, provided they are in line with rates for other sectors.
Read More
AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China
Published: April 29, 2025 by: WSJ
Sentiment: Neutral
The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of up to $8 million in China.
Read More
AstraZeneca shares fall 4% after Q1 revenue miss
Published: April 29, 2025 by: Proactive Investors
Sentiment: Negative
Shares in AstraZeneca PLC (LSE:AZN) fell 4% in early trading after first-quarter revenues missed City forecasts, as investors looked past stronger-than-expected earnings and a standout performance from its oncology portfolio. The Anglo-Swedish drugmaker reiterated its guidance for the full year, forecasting high single-digit percentage growth in total revenue and a low double-digit percentage rise in core earnings per share at constant exchange rates.
Read More
AstraZeneca says may face further import tax fine from China
Published: April 29, 2025 by: Reuters
Sentiment: Negative
AstraZeneca on Tuesday said it had received an opinion from authorities in Shenzhen city of suspected unpaid import taxes of $1.6 million, adding that a fine of one to five times that amount may be levied if the company is found liable.
Read More
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
BOSTON and ROLLE, Switzerland , April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024 , this new phase will extend the test's reach to a total of 30 clinical institutions worldwide in 2025.
Read More
Tempus AI shares jump on new oncology AI partnerships with AstraZeneca, Pathos
Published: April 23, 2025 by: Proactive Investors
Sentiment: Positive
Tempus AI (NASDAQ:TEM) said on Wednesday it has signed multi-year strategic collaborations with AstraZeneca (AZN.L) and Pathos AI to co-develop what it called the largest multimodal foundation model in oncology, sending its shares up more than 15% in morning trading. The deals, which include $200 million in data licensing and model development fees to Tempus, will leverage the company's vast repository of de-identified oncology data and artificial intelligence capabilities to help identify new drug targets and advance cancer therapies.
Read More
AstraZeneca reports best trial results in a decade for metastatic breast cancer treatment
Published: April 22, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) reported notable progress in ongoing trials of patients with metastatic breast cancer using a combination of drugs, Enhertu and pertuzumab. Enhertu, jointly developed by the Anglo-Swedish drug company and Japan's Daiichi Sankyo, is being combined with Roche's pertuzumab in the DESTINY-Breast09 Phase III trials, and showed a statistically significant and clinically meaningful improvement in progression-free survival.
Read More
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, are expected to have driven the company's top line.
Read More
European pharma companies issue demands to stay in EU ahead of expected US tariffs
Published: April 15, 2025 by: Reuters
Sentiment: Negative
Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite threatened U.S. tariffs on imports, including measures to compensate them for the cost of pharmaceutical innovations, French business newspaper Les Echos reported on Tuesday.
Read More
Trump Says Pharmaceutical Tariffs Coming in Near Future
Published: April 14, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Read More
Trump says US pharma tariffs coming in not-too-distant future
Published: April 14, 2025 by: Reuters
Sentiment: Negative
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Read More
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
Published: April 11, 2025 by: CNBC
Sentiment: Negative
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Read More
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.
Read More
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Read More
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Published: April 09, 2025 by: WSJ
Sentiment: Negative
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Read More
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.
Read More
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
Published: April 09, 2025 by: The Motley Fool
Sentiment: Negative
Just like the rest of the stock market, pharmaceutical stocks are in a funk approaching the midweek mark, and it's looking like things might be about to get even worse for this particular pocket of the stock market. On Wednesday, Reuters reported that President Donald Trump is preparing to unveil a new series of tariffs on pharmaceutical imports.
Read More
AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label in lung cancer.
Read More
AstraZeneca and GSK shares rise on possible escape from new US tariffs
Published: April 03, 2025 by: Proactive Investors
Sentiment: Positive
UK pharmaceutical giants AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) shares both avoided the wider sell-off on Thursday morning on hopes that drug imports will escape the new 'reciprocal tariffs'. Based on a clarifying fact sheet produced by the White House alongside President Trump's announcement, it appears that pharmaceutical products imported into the US will be exempt from higher-rate tariffs "At least for now," says analyst Sean Conroy at Shore Capital.
Read More
AstraZeneca remains top pick with leading American bank. Here's why
Published: April 02, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) has kept its spot as Bank of America's top pick in the pharmaceutical sector, with analysts raising their earnings forecasts and praising the company's “best-in-class” drug pipeline. The bank reiterated its 'buy' rating and lifted its price target to 14,500p, pointing to a 28% upside from current levels.
Read More
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
Published: April 01, 2025 by: CNBC
Sentiment: Positive
AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
Read More
Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Negative
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, South Korea , March 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, will present a deep learning study on Epidermal Growth Factor Receptor (EGFR) mutation prediction in patients with non-small cell lung cancer (NSCLC) at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, held from April 25 to 30 in Chicago, Illinois. The study, which highlights the development and validation of the Lunit …
Read More
AstraZeneca and GKS shares have legs, but the weight loss titans will dominate, says investment bank
Published: March 24, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) remain among Berenberg's top picks in the pharmaceuticals sector, with the broker reaffirming its 'buy' rating on both stocks. The former carries a target price of £140, while the valuation for stock in the latter is £16.
Read More
Watch CNBC's full interview with AstraZeneca CEO Pascal Soriot
Published: March 21, 2025 by: CNBC International TV
Sentiment: Positive
Pascal Soriot, CEO of British pharmaceutical giant AstraZeneca, discusses the company's $2.5 billion investment in a new China research and development center.
Read More
Watch CNBC's full interview with Pascal Soriot, AstraZeneca CEO
Published: March 21, 2025 by: CNBC International TV
Sentiment: Positive
Pascal Soriot, CEO, AstraZeneca discusses the company's $2.5 billion investment in its new China research and development centre.
Read More
About AstraZeneca PLC (AZN)
- IPO Date 1993-05-12
- Website https://www.astrazeneca.com
- Industry Drug Manufacturers - General
- CEO Pascal Claude Roland Soriot
- Employees 94300